Drug firm Divis Laboratories is set to announce its September quarter earnings on Monday (November 9). However, on a sequential basis, it is going to be a decline.
The expected revenue growth is around 15 percent and EBITDA (Earnings before interest, taxes, depreciation, and amortization) growth could be around 27 percent.
Margins are expected at 35.3 percent which is an increase of around 400 basis points YoY. Profits too are expected to go up by 23 percent.
For more, watch the video.